Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $184
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Citigroup analyst Yigal Nochomovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $160 to $184.
Citigroup analyst Yigal Nochomovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $160 to $184.